Small cell lung cancer (SCLC), which accounts for about 15% of lung cancer cases, is an aggressive disease characterized by rapid growth and early widespread metastasis. Despite sensitive to chemotherapy and radiotherapy, SCLC is vulnerable to get resistant and has high recurrence rates. In recent years, immunotherapy has shown good antitumor activity, especially programmed death receptor-1/ligand-L1 (PD-1/L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) Checkpoint inhibitors have changed the pattern of tumor treatment, and SCLC has high immunogenicity, high mutation load and other favorable immune factors, so immuno-checkpoint inhibitors may become an important breakthrough in SCLC treatment. This article will briefly review the clinical research of immunotherapy for small cell lung cancer. .
【中文题目：小细胞肺癌免疫治疗研究进展】 【中文摘要：小细胞肺癌（small cell lung cancer, SCLC）约占肺癌的15%，恶性程度高，侵袭性强，尽管其对放化疗比较敏感，但极易发生耐药，复发率高，后期治疗效果欠佳。近年来，免疫抑制剂展现了良好的抗肿瘤活性，特别是程序性死亡受体-1/配体-L1（programmed death receptor-1/ligand-L1, PD-1/L1）和细胞毒性T淋巴细胞相关抗原-4（cytotoxic T-lymphocyte-associated antigen 4, CTLA-4）检查点抑制剂的问世改变了肿瘤治疗的格局，同时SCLC具有高免疫源性，高突变负荷等免疫利好因素，免疫检查点抑制剂有望成为该领域治疗的重要突破口，本文将对SCLC免疫治疗的临床研究进展做简要综述。 】 【中文关键词：肺肿瘤；免疫治疗；临床研究】.
Keywords: Clinical development; Immunotherapy; Lung neoplasms.